0
views
0
recommends
+1 Recommend
2 collections
    0
    shares

      Call for Papers: Digital Diagnostic Techniques

      Submit here before November 30, 2024

      About Pathobiology: 3.5 Impact Factor I 8.5 CiteScore I 1.088 Scimago Journal & Country Rank (SJR)

      Call for Papers: Supportive Care - Essential for Modern Oncology

      Submit here before December 31, 2024

      About Oncology Research and Treatment: 2.0 Impact Factor I 3.2 CiteScore I 0.521 Scimago Journal & Country Rank (SJR)

      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Enrichment of Immune-Related Genes in Aggressive Primary Breast Angiosarcoma: A Case Report

      case-report

      Read this article at

      ScienceOpenPublisherPMC
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Primary breast angiosarcoma is an extremely rare disease with a poor prognosis. Primary angiosarcoma is distinct from secondary angiosarcoma, which usually occurs in patients who have been previously treated for breast cancer. The low incidence of primary breast angiosarcoma has hindered the elucidation of its etiology and potential therapies. Here, we report a case of a patient with primary breast angiosarcoma who experienced recurrence after surgery. The tumor was refractory to systemic treatments, and the patient died 18 months after the surgery. We used RNA sequencing for gene expression profiling of the tumor. A high tumor inflammation signature score indicated enrichment in immune-related signaling. CIBERSORTx, a tool used to characterize the cellular composition of complex tissues based on gene expression, indicated that the immune cells in the tumor were predominantly macrophages, and this was confirmed using immunohistochemical analysis. These findings indicate the possible use of checkpoint immunotherapy for the treatment of primary breast angiosarcoma.

          Related collections

          Most cited references25

          • Record: found
          • Abstract: found
          • Article: not found

          Macrophage activation and polarization: nomenclature and experimental guidelines.

          Description of macrophage activation is currently contentious and confusing. Like the biblical Tower of Babel, macrophage activation encompasses a panoply of descriptors used in different ways. The lack of consensus on how to define macrophage activation in experiments in vitro and in vivo impedes progress in multiple ways, including the fact that many researchers still consider there to be only two types of activated macrophages, often termed M1 and M2. Here, we describe a set of standards encompassing three principles-the source of macrophages, definition of the activators, and a consensus collection of markers to describe macrophage activation-with the goal of unifying experimental standards for diverse experimental scenarios. Collectively, we propose a common framework for macrophage-activation nomenclature. Copyright © 2014 Elsevier Inc. All rights reserved.
            Bookmark
            • Record: found
            • Abstract: not found
            • Article: not found

            Tumor Mutational Burden and Response Rate to PD-1 Inhibition

              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Pembrolizumab for Early Triple-Negative Breast Cancer

              Previous trials showed promising antitumor activity and an acceptable safety profile associated with pembrolizumab in patients with early triple-negative breast cancer. Whether the addition of pembrolizumab to neoadjuvant chemotherapy would significantly increase the percentage of patients with early triple-negative breast cancer who have a pathological complete response (defined as no invasive cancer in the breast and negative nodes) at definitive surgery is unclear.
                Bookmark

                Author and article information

                Journal
                Case Rep Oncol
                Case Rep Oncol
                CRO
                CRO
                Case Reports in Oncology
                S. Karger AG (Basel, Switzerland )
                1662-6575
                3 July 2023
                Jan-Dec 2023
                3 July 2023
                : 16
                : 1
                : 455-464
                Affiliations
                [a ]Department of Breast Surgery, Shizuoka Prefectural Hospital Organization, Shizuoka General Hospital, Shizuoka, Japan
                [b ]Division of Medical Oncology, National Cancer Center Singapore, Singapore, Singapore
                [c ]Evolutionary Medicine, Shizuoka Graduate University of Public Health, Shizuoka, Japan
                [d ]Division of Medical Oncology, Shizuoka Prefectural Hospital Organization, Shizuoka General Hospital, Shizuoka, Japan
                [e ]Department of Pathology, Shizuoka Prefectural Hospital Organization, Shizuoka General Hospital, Shizuoka, Japan
                Author notes
                Correspondence to: Ryoichi Matsunuma, r-matsunuma@ 123456nifty.com
                Article
                531490
                10.1159/000531490
                10368090
                37497424
                b502c957-d433-4d73-b27f-022aa36d28d6
                © 2023 The Author(s). Published by S. Karger AG, Basel

                This article is licensed under the Creative Commons Attribution-NonCommercial 4.0 International License (CC BY-NC) ( http://www.karger.com/Services/OpenAccessLicense). Usage and distribution for commercial purposes requires written permission.

                History
                : 6 March 2023
                : 24 May 2023
                : 2023
                Page count
                Figures: 4, References: 25, Pages: 10
                Funding
                This work was supported by JSPS KAKENHI (Grant No. 21K08612) to R.M. and the Medical Research Support Project of Shizuoka Prefectural Hospital Organization to R.M. The funders had no role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript.
                Categories
                Case Report

                Oncology & Radiotherapy
                angiosarcoma,breast,next-generation sequencing,immune cell,macrophage
                Oncology & Radiotherapy
                angiosarcoma, breast, next-generation sequencing, immune cell, macrophage

                Comments

                Comment on this article